Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

67 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
Lunniss GE, Barnes AA, Barton N, Biagetti M, Bianchi F, Blowers SM, Caberlotto LL, Emmons A, Holmes IP, Montanari D, Norris R, Puckey GV, Walters DJ, Watson SP, Willis J. Lunniss GE, et al. Among authors: montanari d. Bioorg Med Chem Lett. 2010 Dec 15;20(24):7341-4. doi: 10.1016/j.bmcl.2010.10.065. Epub 2010 Nov 10. Bioorg Med Chem Lett. 2010. PMID: 21074426
The identification of structurally novel, selective, orally bioavailable positive modulators of mGluR2.
D'Alessandro PL, Corti C, Roth A, Ugolini A, Sava A, Montanari D, Bianchi F, Garland SL, Powney B, Koppe EL, Rocheville M, Osborne G, Perez P, de la Fuente J, De Los Frailes M, Smith PW, Branch C, Nash D, Watson SP. D'Alessandro PL, et al. Among authors: montanari d. Bioorg Med Chem Lett. 2010 Jan 15;20(2):759-62. doi: 10.1016/j.bmcl.2009.11.032. Epub 2009 Nov 26. Bioorg Med Chem Lett. 2010. PMID: 20005096
The identification a novel, selective, non-steroidal, functional glucocorticoid receptor antagonist.
Rimland J, Dunne A, Hunjan SS, Sasse R, Uings I, Montanari D, Caivano M, Shah P, Standing D, Gray D, Brown D, Cairns W, Trump R, Smith PW, Bertheleme N, D'Alessandro P, Gul S, Vimal M, Smith DN, Watson SP. Rimland J, et al. Among authors: montanari d, d alessandro p. Bioorg Med Chem Lett. 2010 Apr 1;20(7):2340-3. doi: 10.1016/j.bmcl.2010.01.133. Epub 2010 Feb 4. Bioorg Med Chem Lett. 2010. PMID: 20202837
Discovery process and pharmacological characterization of 2-(S)-(4-fluoro-2-methylphenyl)piperazine-1-carboxylic acid [1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]methylamide (vestipitant) as a potent, selective, and orally active NK1 receptor antagonist.
Di Fabio R, Griffante C, Alvaro G, Pentassuglia G, Pizzi DA, Donati D, Rossi T, Guercio G, Mattioli M, Cimarosti Z, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M. Di Fabio R, et al. Among authors: montanari d. J Med Chem. 2009 May 28;52(10):3238-47. doi: 10.1021/jm900023b. J Med Chem. 2009. PMID: 19388677
Discovery and biological characterization of (2R,4S)-1'-acetyl-N-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-2-(4-fluoro-2-methylphenyl)-N-methyl-4,4'-bipiperidine-1-carboxamide as a new potent and selective neurokinin 1 (NK1) receptor antagonist clinical candidate.
Di Fabio R, Alvaro G, Griffante C, Pizzi DA, Donati D, Mattioli M, Cimarosti Z, Guercio G, Marchioro C, Provera S, Zonzini L, Montanari D, Melotto S, Gerrard PA, Trist DG, Ratti E, Corsi M. Di Fabio R, et al. Among authors: montanari d. J Med Chem. 2011 Feb 24;54(4):1071-9. doi: 10.1021/jm1013264. Epub 2011 Jan 13. J Med Chem. 2011. PMID: 21229983
Role of orexin-1 receptor mechanisms on compulsive food consumption in a model of binge eating in female rats.
Piccoli L, Micioni Di Bonaventura MV, Cifani C, Costantini VJ, Massagrande M, Montanari D, Martinelli P, Antolini M, Ciccocioppo R, Massi M, Merlo-Pich E, Di Fabio R, Corsi M. Piccoli L, et al. Among authors: montanari d. Neuropsychopharmacology. 2012 Aug;37(9):1999-2011. doi: 10.1038/npp.2012.48. Epub 2012 May 9. Neuropsychopharmacology. 2012. PMID: 22569505 Free PMC article.
GSK356278, a potent, selective, brain-penetrant phosphodiesterase 4 inhibitor that demonstrates anxiolytic and cognition-enhancing effects without inducing side effects in preclinical species.
Rutter AR, Poffe A, Cavallini P, Davis TG, Schneck J, Negri M, Vicentini E, Montanari D, Arban R, Gray FA, Davies CH, Wren PB. Rutter AR, et al. Among authors: montanari d. J Pharmacol Exp Ther. 2014 Jul;350(1):153-63. doi: 10.1124/jpet.114.214155. Epub 2014 Apr 30. J Pharmacol Exp Ther. 2014. PMID: 24784567
67 results